Regeneron Pharmaceuticals REGN Net debt / EBITDA
Net debt / EBITDA at other companies
Other financials
Where this comes from
Calculated from Regeneron Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's net debt / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's net debt / EBITDA?
- Regeneron Pharmaceuticals (REGN) reported net debt / EBITDA of -0.1× in Q1 2026.
- How has Regeneron Pharmaceuticals's net debt / EBITDA changed year-over-year?
- Regeneron Pharmaceuticals's net debt / EBITDA increased by 29.3% year-over-year, from -0.1× to -0.1×.
- What is the long-term trend for Regeneron Pharmaceuticals's net debt / EBITDA?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's net debt / EBITDA has grown at a -26.3% compound annual growth rate (CAGR), from 0.3× to 0.1×.
- What does net debt / EBITDA mean?
- How many years of operating earnings it would take to pay off the company's net debt.
- How do you interpret net debt / EBITDA?
- Lower is safer; lenders often covenant around 3–4×. A negative value means net cash (more cash than debt), a position of strength. Spikes can reflect a temporary EBITDA dip rather than new borrowing.
- How does net debt / EBITDA compare across companies?
- A standard leverage yardstick across non-financial sectors; covenant thresholds vary by industry cash-flow stability.